Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

被引：0
|
作者：
Leonie JM Mekenkamp
Jolien Tol
Jeroen R Dijkstra
Inge de Krijger
M Elisa Vink-Börger
Shannon van Vliet
Steven Teerenstra
Eveline Kamping
Eugène Verwiel
Miriam Koopman
Gerrit A Meijer
J Han JM van Krieken
Roland Kuiper
Cornelis JA Punt
Iris D Nagtegaal
机构：
[1] Radboud University Nijmegen Medical Centre,Department of Medical Oncology
[2] Radboud University Nijmegen Medical Centre,Department of Pathology
[3] Radboud University Nijmegen Medical Centre,Department of Epidemiology, Biostatistics and Health Technology Assessment
[4] Radboud University Nijmegen Medical Centre,Department of Human Genetics
[5] University Medical Center Utrecht,Department of Medical Oncology
[6] VU University Medical Center,Department of Pathology
[7] University of Amsterdam,Department of Medical Oncology, Academic Medical Centre
来源：
BMC Cancer | / 12卷
关键词：
Cetuximab; KRAS Mutation; Copy Number Change; Poor Responder; Copy Number Gain;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
    Mekenkamp, Leonie J. M.
    Tol, Jolien
    Dijkstra, Jeroen R.
    de Krijger, Inge
    Vink-Borger, M. Elisa
    van Vliet, Shannon
    Teerenstra, Steven
    Kamping, Eveline
    Verwiel, Eugene
    Koopman, Miriam
    Meijer, Gerrit A.
    van Krieken, J. Han J. M.
    Kuiper, Roland
    Punt, Cornelis J. A.
    Nagtegaal, Iris D.
    BMC CANCER, 2012, 12
  • [2] Beyond KRAS mutation status: Influence of KRAS copy number alteration and microRNAs in response to cetuximab in metastatic colorectal cancer patients
    Mekenkamp, Leonie J. M.
    Tol, Jolien
    Dijkstra, Jeroen
    De Krijger, Inge
    Vink-Borger, M. Elisa
    Teerenstra, Steven
    Verwiel, Eugene
    Koopman, Miriam
    Meijer, Gerrit A.
    van Krieken, J. Han J. M.
    Kuiper, Roland
    Punt, Cornelis J. A.
    Nagtegaa, Iris D.
    CANCER RESEARCH, 2011, 71
  • [3] First-line therapy with cetuximab followed by cetuximab plus folfiri in patients with metastatic colorectal cancer: KRAS mutation status correlates with clinical outcome
    Martinelli, E.
    Macarulia, T.
    Vega-Villegas, E.
    Rodriguez-Braun, E.
    Ciardiello, F.
    Ramos, F.
    Rivera, F.
    Stroh, C.
    Nippgen, J.
    Cervantes, A.
    Baselga, J.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [4] KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer
    Radanova, Maria
    Mihaylova, Galya
    St Stoyanov, George
    Draganova, Vyara
    Zlatarov, Aleksandar
    Kolev, Nikola
    Dimitrova, Eleonora
    Conev, Nikolay
    Ivanova, Diana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)
  • [5] GENETIC ANALYSIS OF KRAS MUTATION STATUS IN METASTATIC COLORECTAL CANCER PATIENTS
    Zavodna, K.
    Konecny, M.
    Spanik, S.
    Galbavy, S.
    Vizvaryova, M.
    Weismanova, E.
    Kausitz, J.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4015 - 4016
  • [6] Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients
    Zavodna, K.
    Konecny, M.
    Krivulcik, T.
    Spanik, S.
    Behulova, R.
    Vizvaryova, M.
    Weismanova, E.
    Galbavy, S.
    Kausitz, J.
    NEOPLASMA, 2009, 56 (03) : 275 - 278
  • [7] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Lièvre, A
    Bachet, JB
    Le Corre, D
    Boige, V
    Landi, B
    Emile, JF
    Côté, JF
    Tomasic, G
    Penna, C
    Ducreux, M
    Rougier, P
    Penault-Llorca, F
    Laurent-Puig, P
    CANCER RESEARCH, 2006, 66 (08) : 3992 - 3995
  • [8] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Lievre, A.
    Bachet, J.
    Boige, V
    Landi, B.
    Emile, J.
    Cote, J.
    Tomasic, G.
    Rougier, P.
    Penault-Llorca, F.
    Laurent-Puig, P.
    ANNALS OF ONCOLOGY, 2006, 17 : 42 - 42
  • [9] KRAS mutation status, comorbidity, and mortality in patients with metastatic colorectal cancer in Denmark
    Ording, Anne Gulbech
    Oztuerk, Buket
    Spindler, Karen-Lise Garm
    Sorensen, Henrik Toft
    McCusker, Margaret
    Ehrenstein, Vera
    ACTA ONCOLOGICA, 2018, 57 (12) : 1727 - 1729
  • [10] Implications of KRAS mutation status for the treatment of metastatic colorectal cancer
    Ciardiello, Fortunato
    Tejpar, Sabine
    Papamichael, Demetris
    TARGETED ONCOLOGY, 2009, 4 (04) : 311 - 322
12345